Eyepoint Pharmaceuticals Inc Cash Flow Conversion Efficiency
Eyepoint Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Eyepoint Pharmaceuticals Inc (EYPT) has a cash flow conversion efficiency ratio of -0.297x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.35 Million) by net assets ($200.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eyepoint Pharmaceuticals Inc (2002–2024)
Cash flow conversion efficiency of Eyepoint Pharmaceuticals Inc from 2002 to 2024. This chart illustrates how Eyepoint Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Eyepoint Pharmaceuticals Inc stock quote for real-time trading data and today's change.
Eyepoint Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Eyepoint Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eyepoint Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eyepoint Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Eyepoint Pharmaceuticals Inc (EYPT) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ROYAL ROAD MIN.
F:RLU
|
-0.125x |
|
EP Manufacturing Bhd
KLSE:7773
|
-0.008x |
|
Globus Maritime Ltd
NASDAQ:GLBS
|
0.020x |
|
Yiren Digital Ltd
F:19YA
|
0.040x |
|
Subur Tiasa Holdings Bhd
KLSE:6904
|
0.003x |
|
Kekrops S.A.
AT:KEKR
|
-0.005x |
|
Gyeongnam Steel Co. Ltd
KQ:039240
|
0.037x |
|
Vate Technology Co Ltd
TWO:5344
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Eyepoint Pharmaceuticals Inc (2002–2024)
The table below shows the annual cash flow conversion efficiency of Eyepoint Pharmaceuticals Inc from 2002 to 2024. Review Eyepoint Pharmaceuticals Inc (EYPT) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $336.50 Million | $-126.23 Million | -0.375x | -5428.07% |
| 2023-12-31 | $266.32 Million | $1.88 Million | 0.007x | +101.04% |
| 2022-12-31 | $96.37 Million | $-65.00 Million | -0.675x | -148.27% |
| 2021-12-31 | $184.38 Million | $-50.10 Million | -0.272x | +65.10% |
| 2020-12-31 | $18.54 Million | $-14.44 Million | -0.779x | +88.56% |
| 2019-12-31 | $8.33 Million | $-56.70 Million | -6.807x | -263.12% |
| 2018-12-31 | $11.69 Million | $-21.91 Million | -1.874x | -22.00% |
| 2017-12-31 | $13.34 Million | $-20.49 Million | -1.536x | -96.63% |
| 2016-12-31 | $20.88 Million | $-16.32 Million | -0.781x | -277.33% |
| 2015-12-31 | $23.37 Million | $10.30 Million | 0.441x | +161.63% |
| 2014-12-31 | $14.92 Million | $-10.67 Million | -0.715x | +37.04% |
| 2013-12-31 | $7.70 Million | $-8.74 Million | -1.136x | -72.05% |
| 2012-12-31 | $13.64 Million | $-9.00 Million | -0.660x | -679.47% |
| 2011-12-31 | $37.43 Million | $-3.17 Million | -0.085x | -128.27% |
| 2010-12-31 | $33.04 Million | $9.90 Million | 0.300x | +183.60% |
| 2009-12-31 | $23.54 Million | $-8.44 Million | -0.358x | -51.84% |
| 2008-12-31 | $21.79 Million | $-5.14 Million | -0.236x | +26.68% |
| 2007-12-31 | $65.91 Million | $-21.21 Million | -0.322x | -32.04% |
| 2006-12-31 | $66.20 Million | $-16.14 Million | -0.244x | -58.47% |
| 2005-12-31 | $60.74 Million | $-9.34 Million | -0.154x | 0.00% |
| 2004-12-31 | $60.74 Million | $-9.34 Million | -0.154x | +24.42% |
| 2003-12-31 | $26.70 Million | $-5.44 Million | -0.204x | +71.85% |
| 2002-12-31 | $4.23 Million | $-3.06 Million | -0.723x | -- |
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more